135 related articles for article (PubMed ID: 19640209)
1. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.
Bobo WV; Shelton RC
Expert Opin Pharmacother; 2009 Sep; 10(13):2145-59. PubMed ID: 19640209
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Bobo WV; Shelton RC
Expert Rev Neurother; 2010 May; 10(5):651-70. PubMed ID: 20420487
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.
Bobo WV; Shelton RC
Neuropsychiatr Dis Treat; 2009; 5():369-83. PubMed ID: 19590732
[TBL] [Abstract][Full Text] [Related]
4. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Rothschild AJ; Williamson DJ; Tohen MF; Schatzberg A; Andersen SW; Van Campen LE; Sanger TM; Tollefson GD
J Clin Psychopharmacol; 2004 Aug; 24(4):365-73. PubMed ID: 15232326
[TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of olanzapine/fluoxetine combination.
Cristancho MA; Thase ME
Expert Opin Drug Saf; 2014 Aug; 13(8):1133-41. PubMed ID: 24972823
[TBL] [Abstract][Full Text] [Related]
8. Clinical highlights in bipolar depression: focus on atypical antipsychotics.
Calabrese JR; Elhaj O; Gajwani P; Gao K
J Clin Psychiatry; 2005; 66 Suppl 5():26-33. PubMed ID: 16038599
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine-fluoxetine combination for the treatment of bipolar depression.
Citrome L
Expert Opin Pharmacother; 2011 Dec; 12(17):2751-8. PubMed ID: 22035291
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
Thase ME; Corya SA; Osuntokun O; Case M; Henley DB; Sanger TM; Watson SB; Dubé S
J Clin Psychiatry; 2007 Feb; 68(2):224-36. PubMed ID: 17335320
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Brunner E; Tohen M; Osuntokun O; Landry J; Thase ME
Neuropsychopharmacology; 2014 Oct; 39(11):2549-59. PubMed ID: 24801768
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Cruz N; Sanchez-Moreno J; Torres F; Goikolea JM; Valentí M; Vieta E
Int J Neuropsychopharmacol; 2010 Feb; 13(1):5-14. PubMed ID: 19638254
[TBL] [Abstract][Full Text] [Related]
14. Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment.
Mncube K; Harvey BH
IBRO Neurosci Rep; 2022 Dec; 13():284-298. PubMed ID: 36204253
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of new second generation antipsychotics for major depressive disorder.
McElroy SL; Guerdjikova A; Mori N; Keck PE
Expert Opin Investig Drugs; 2010 Dec; 19(12):1527-44. PubMed ID: 21105856
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
Tohen M; Case M; Trivedi MH; Thase ME; Burke SJ; Durell TM
J Clin Psychiatry; 2010 Apr; 71(4):451-62. PubMed ID: 20361905
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vitro percutaneous absorption of olanzapine and fluoxetine HCl: enhancement properties of olanzapine.
Borovinskaya M; Robert B; Plakogiannis FM
Drug Dev Ind Pharm; 2012 Feb; 38(2):227-34. PubMed ID: 21864096
[TBL] [Abstract][Full Text] [Related]
18. Treatment of bipolar depression: making sensible decisions.
Citrome L
CNS Spectr; 2014 Dec; 19 Suppl 1():4-11; quiz 1-3, 12. PubMed ID: 25407667
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.
Croxtall JD; Scott LJ
CNS Drugs; 2010 Mar; 24(3):245-62. PubMed ID: 20155998
[TBL] [Abstract][Full Text] [Related]
20. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
